Agios Pharmaceuticals (AGIO)
Commercializes mitapivat for rare blood disorders and develops additional hematology therapies.
$34.30
Pre-market+0.16 (+0.47%)
At close$34.14(−0.20%)
Something off on this page? Send us feedback.
Next report
Oct 29, 2026
in 56 days
EPS estimate
−$1.21
Revenue estimate
$53.8M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported−$1.74−$1.55−$1.93−$1.78−$1.85−$1.69−$1.69Pending
Estimate−$1.69−$1.80−$1.74−$1.93−$1.97−$1.81−$1.65−$1.21
Surprise−3.0%+13.9%−10.9%+7.8%+6.1%+6.6%−2.4%—
RevenueReportedEstimate
Feb '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$10.7M$8.7M$12.5M$12.9M$20.0M$20.7M$44.7MPending
Estimate$9.3M$10.0M$10.3M$11.7M$12.1M$13.3M$26.4M$53.8M
Surprise+14.8%−12.6%+21.2%+10.1%+65.1%+56.0%+69.5%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | −$1.21 | — | — |
| Jul 2026 | −$1.65 | −$1.69 | −2.4% |
| Apr 2026 | −$1.81 | −$1.69 | +6.6% |
| Feb 2026 | −$1.97 | −$1.85 | +6.1% |
| Oct 2025 | −$1.93 | −$1.78 | +7.8% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | −$1.21 | — | — | $53.8M | — | — | — |
| Jul 30, 2026 | −$1.65 | −$1.69 | −2.4% | $26.4M | $44.7M | +69.5% | −6.5% |
| Apr 29, 2026 | −$1.81 | −$1.69 | +6.6% | $13.3M | $20.7M | +56.0% | −0.2% |
| Feb 12, 2026 | −$1.97 | −$1.85 | +6.1% | $12.1M | $20.0M | +65.1% | −0.4% |
| Oct 30, 2025 | −$1.93 | −$1.78 | +7.8% | $11.7M | $12.9M | +10.1% | +0.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Jul 31, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 13, 2025 | |||||||
| Oct 31, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 15, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 23, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 24, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Jul 29, 2021 | |||||||
| Apr 29, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Jul 30, 2020 | |||||||
| Apr 30, 2020 | |||||||
| Feb 13, 2020 | |||||||
| Oct 31, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 2, 2019 | |||||||
| Feb 14, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 4, 2018 | |||||||
| Feb 14, 2018 | |||||||
| Nov 1, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 4, 2017 | |||||||
| Feb 16, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 18, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Aug 6, 2015 | |||||||